Newswise — AMES, Iowa – Setbacks are to be expected when pursuing a goal, whether you are trying to lose weight or save money. The challenge is getting back on track and not giving up after a difficulty or crisis, says a marketing professor in Iowa State University’s Ivy College of Business. José Rosa, John and Deborah Ganoe Faculty Fellow, is part of a research team working on practical ways to help people stick to health-related goals – specifically, prescribed regimens for medical ailments that require significant lifestyle changes. The work is personal for Rosa. His diabetic sister nearly died when her blood sugar hit dangerously high levels, and she struggles with poor vision and health, he said. Staying committed to a long-term health goal is challenging, because it may feel as if there is no light at the end of the tunnel, Rosa said. If your goal is to lose 20 pounds, there is a defined timeframe and a point to celebrate achieving your goal. However, if you are diabetic and need to cut certain foods from your diet or change your daily routine to exercise more, the goal has a different feel, Rosa said. “These are some of the most difficult goals we face, because the effort has to become a way of life. If you’re a diabetic, you have to be thinking about your diet every time you eat,” Rosa said. “In many ways, it is sacrificial. You must endure this cost and the reward is health.” Unfortunately, the reward is not immediate and often difficult to realize with certain ailments, such as diabetes or high blood pressure. As we age, other health issues can complicate the outcome of the initial goal and appear as if our efforts are not paying off. This makes it harder to stick to the goal, Rosa said, even though we know giving up can have serious consequences. Rosa and Richard Vann, lead author and assistant professor at Penn State Behrend in Erie, Pennsylvania; and Sean McCrea, associate professor at the University of Wyoming, conducted five experiments to understand how crisis influences motivation and commitment to the goal. They found a setback or difficulty often prompts people to reassess the cost-benefits of the goal and consider quitting. The results are published online in the journal Psychology & Marketing. Setback can snowball The experiments simulated a series of situations in which some participants faced an action crisis. They then answered several questions to determine how they would react. Rosa says an action crisis may be related or unrelated to the goal, but it is a point during goal pursuit when circumstances change, causing us to question whether the goal really matters. Once that questioning begins, we shift our mindset from implementation to evaluation. We renegotiate the importance of the outcomes and may determine it is no longer worth it, Rosa said. The researchers refer to that decision to quit as “taking the off ramp,” which can snowball into other problems. “We know it’s hard to get back on once people take the off ramp. This causes some people to feel like failures and stop trying all together. In some situations, the off ramp leads to behaviors that cause another crisis or a significant decline,” he said. For example, Rosa says a man with high blood pressure stops taking his medication and suffers a heart attack, or a diabetic woman has an insulin reaction causing her to black out and crash her car. Intervention to prevent renegotiation Researchers are now using data from the experiments to develop and test interventions for patients on prescribed health regimens. Rosa says the goal is to provide specific instructions for patients to follow and help shift their mindset from renegotiation or evaluation back to implementation. The potential benefit of such an intervention extends beyond the individual patient, Rosa said. From a marketing perspective, it is an issue of consumption and making health care more effective for patients. Rosa says the right intervention will help patients stay on track, lessening the risk for additional health issues and lowering health care costs.
Newswise — JUPITER, FL – June 21, 2018 – About half of all drugs, ranging from morphine to penicillin, come from compounds that are from—or have been derived from—nature. This includes many cancer drugs, which are toxic enough to kill cancer cells. So how do the organisms that make these toxic substances protect themselves from the harmful effects? Scientists on the Florida campus of Scripps Research have uncovered a previously unknown mechanism—proteins that cells use to bind to a toxic substance and sequester it from the rest of the organism. “Thanks to this discovery, we now know something about the mechanisms of resistance that’s never been known before for the enediyne antitumor antibiotics,” says study senior author Ben Shen, PhD, professor and co-chair of the Scripps Research Department of Chemistry. The work has important implications for understanding how human cancer cells develop resistance to natural product-based chemotherapies. Furthermore, the microbiome may play a role in drug resistance. The study was published today in the journal Cell Chemical Biology. “This mechanism could be clinically relevant for patients getting these drugs, so it’s very important to study it further,” says Shen. Natural products—chemical compounds produced by living organisms—are considered one of the best sources of new drugs and drug leads. “They possess enormous structural and chemical diversity compared with molecules that are made in the lab,” Shen says. Natural products may come from flowers, trees or marine organisms such as sponges. One of the most common sources, however, is soil-dwelling bacteria. Shen’s lab is focused on a class of natural products called enediynes. These compounds come from bacteria called actinomycetes, which are naturally found in the soil. Two enediyne products are already FDA approved as cancer drugs and are in wide use. But patients who take them often develop resistance. After a period of months or years, tumors can stop responding to the chemotherapy and begin growing again. While how patients develop resistance to these drugs remains largely unknown, scientists have uncovered two mechanisms that bacteria use to protect themselves from enediynes. “Mechanisms of self-resistance in antibiotic producers serve as outstanding models to predict and combat future drug resistance in a clinical setting,” says Shen. In the new study, researchers report a third, previously undiscovered resistance mechanism. It involves three genes called tnmS1, tnmS2 and tnmS3, which encode proteins that allow bacteria to resist the effects of a type of enediynes called tiancimycins. Shen’s lab is currently studying tiancimycins, which hold great promise for new cancer drugs. The proteins work by binding to tiancimycins and keeping them separate from the rest of the organism. After discovering these genes in actinomycetes and how they work, the investigators studied how widespread these genes are in other microorganisms. They were surprised to find that in addition to actinomycetes, the genes were also present in several microorganisms commonly found in the human microbiota, the collection of microorganisms that naturally inhabit the human body. “This raises a lot of questions that no one has ever asked before,” Shen says. “I can rationalize why the producing organism would have these genes, because it needs to protect itself from its own metabolites. But why do other microorganisms need these resistance genes?” He notes that it may be possible for gut microbes to pass the products of these genes on to their host—humans—which could contribute to drug resistance. “These findings raise the possibility that the human microbiota might impact the efficacy of enediyne-based drugs and should be taken into consideration when developing new chemotherapies,” Shen says. “Future efforts to survey the human microbiome for resistance elements should be an important part of natural product-based drug discovery programs.” Other authors of the study, “Resistance to Enediyne Antitumor Antibiotics by Sequestration,” were Chin-Yuan Chang, Xiaohui Yan, Ivana Crnovcic, Thibault Annaval, Jeffrey D. Rudolf, Dong Yang and Hindra, of Scripps Research, George N. Phillips, Jr. of Rice University, and Changsoo Chang, Boguslaw Nocek, Gyorgy Babnigg and Andrzej Joachimiak of Argonne National Laboratory. This research was funded by the National Institutes of Health (grants GM098248, GM109456, GM121060, GM094585, CA078747, GM115575 and CA204484) and the Department of Energy, Office of Biological and Environmental Research (grant DE-AC02-06CH11357). About Scripps Research Scripps Research is one of the world's preeminent independent, not-for-profit organizations focusing on research in the biomedical sciences. Scripps Research is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Science, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.
Unusually High Levels of Herpesviruses Found in the Alzheimer’s Disease Brain, Mount Sinai Researchers Report Networks identified for developing new therapies to treat Alzheimer’s disease Newswise — NEW York, NY (June 21, 2018) Two strains of human herpesvirus—human herpesvirus 6A (HHV-6A) and human herpesvirus 7 (HHV-7) —are found in the brains of people with Alzheimer’s disease at levels up to twice as high as in those without Alzheimer’s, researchers from the Icahn School of Medicine at Mount Sinai report. Using evidence from postmortem brain tissue from the Mount Sinai Brain Bank, the research team also identified previously unknown gene networks that will both offer new testable hypotheses for understanding Alzheimer’s pathology and reveal novel potential targets for new drugs that may arrest Alzheimer's disease progression, and could potentially prevent the disease if administered early enough. This is the first study to use a data-driven approach to study the impact of viruses on Alzheimer’s and to identify the role of HHV-6A and HHV-7 in the disease. This is also the first evidence that integration of HHV genomes into human brain genomes may play a role in the etiology of Alzheimer’s. These viruses can cause encephalitis and other chronic conditions. Results of the study will be published online in Neuron, at 11 am EDT on Thursday, June 21. The research team initially performed RNA sequencing on four brain regions in more than 600 samples of postmortem tissue from people with and without Alzheimer’s to quantify which genes were present in the brain, and whether any were associated with the onset and progression of Alzheimer’s. Through a variety of computational approaches, the team uncovered a complex network of unexpected associations, linking specific viruses with different aspects of Alzheimer’s biology. They examined the influence of each virus on specific genes and proteins in brain cells, and identified associations between specific viruses and amyloid plaques, neurofibrillary tangles, and clinical dementia severity. To evaluate the robustness of their findings, the team incorporated a further 800 RNA sequencing samples collected by the Mayo Clinic and Rush Alzheimer’s Disease Center, observing a persistent increase of HHV-6A and HHV-7 abundance in samples from individuals with Alzheimer’s, thus replicating their main findings in two additional, independent, geographically dispersed cohorts. Every 65 seconds, someone in the United States develops Alzheimer’s. In 2018, the costs of providing care to individuals with Alzheimer’s and other dementias are expected to total more than $277 billion. By mid-century, a new diagnosis will occur every 33 seconds, and costs are expected to exceed $1 trillion annually. Despite the dire public health implications, Alzheimer’s remains the only Top 10 cause of mortality in the United States for which no disease-modifying treatments are available. This study has been enabled by the extensive molecular profiling of several large patient cohorts, generated in the course of the National Institute on Aging (NIA) Accelerating Medicines Partnership-Alzheimer's Disease (AMP-AD). AMP-AD is a precompetitive partnership among government, industry, and nonprofit organizations that focuses on discovering novel, clinically relevant therapeutic targets and on developing biomarkers to help validate existing therapeutic targets. This multisector partnership is managed by the Foundation for the NIH. The combined funding support for this five-year endeavor is $185.2 million. Through the generation of this large, “multi-omic” resource, the team was able to perform their investigation of viral activity in Alzheimer’s in an entirely data-driven manner. The term “multi-omic” is used as shorthand to imply that data from genes, proteins, fats, and other tissue components are all assessed and then represented qualitatively and quantitatively in a complex mathematical model. “This study represents a significant advancement in our understanding of the plausibility of the pathogen hypothesis of Alzheimer’s,” said the study’s senior author, Joel Dudley, PhD, Director of the Institute for Next Generation Healthcare at the Icahn School of Medicine at Mount Sinai. “Our work identified specific biological networks that offer new testable hypotheses regarding the role of microbial defense and innate immune function in the pathophysiology of Alzheimer’s. If it becomes evident that specific viral species directly contribute to an individual’s risk of developing Alzheimer’s or their rate of progression once diagnosed, then this would offer a new conceptual framework for understanding the emergence and evolution of Alzheimer’s at individual, as well as population, levels.” Dr. Dudley notes that this study could potentially translate to the identification of virus, or virus-related, biomarkers that could improve patient risk stratification and diagnosis, as well as implying novel viral targets and biological pathways that could be addressed with new preventative and therapeutic drugs. As with any complex set of findings, they will need to be confirmed in additional patient cohorts, and further studies to specifically address a causal role for viruses are now being conducted by the research team. “This is the most compelling evidence ever presented that points to a viral contribution to the cause or progression of Alzheimer’s,” said one of the study’s authors, Sam Gandy, MD, PhD, Professor of Neurology and Psychiatry and Director of the Center for Cognitive Health and NFL Neurological Care at Mount Sinai. “A similar situation arose recently in certain forms of Lou Gehrig’s disease. In those patients, viral proteins were discovered in the spinal fluid of some Lou Gehrig’s patients, and patients with positive viral protein tests in their spinal fluid showed benefit when treated with antiviral drugs.” Other Mount Sinai authors of the study include co-first authors Ben Readhead, MBBS, and Jean-Vianney Haure-Mirande, PhD. Other Mount Sinai authors include Vahram Haroutounian, PhD, Professor of Psychiatry and Neurobiology and Director of the NeuroBioBank; Mary Sano, PhD, Director of Alzheimer’s Disease Research; Noam Beckmann, PhD candidate; Eric Schadt, PhD, Dean for Precision Medicine and Professor of Genetics and Genomic Sciences; and Michelle Ehrlich, MD, Professor of Neurology, Pediatrics, and Genetics and Genomics Sciences. Postmortem brain tissue was collected through the NIH-designated NeuroBioBank (NBB) System that contributes to support of the Mount Sinai VA/Alzheimer’s Disease Research Center Brain Bank (AG005138). The Dudley Laboratory at the Icahn School of Medicine at Mount Sinai has an institutional partnership with Banner-ASU Neurodegenerative Disease Research Center. Postmortem brain tissue was collected through the NIH-designated NeuroBioBank (NBB) System that contributes to support of the Mount Sinai VA/Alzheimer’s Disease Research Center Brain Bank (AG005138). Dr. Vahram Haroutunian from the Mount Sinai School of Medicine is Director of the NeuroBioBank. Additional postmortem data collection was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, R01 NS080820, Cure PSP Foundation, and support from Mayo Foundation, U24 NS072026, P30 AG19610, Michael J. Fox Foundation for Parkinson’s Research P30AG10161, R01AG15819, R01AG17917, R01AG30146, R01AG36836, U01AG32984, U01AG46152, the Illinois Department of Public Health, and the Translational Genomics Research Institute. Additional work performed in this study was supported by U01 AG046170, R56AG058469, and philanthropic financial support was provided by Katherine Gehl. About the Mount Sinai Health System The Mount Sinai Health System is New York City’s largest integrated delivery system encompassing seven hospital campuses, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai’s vision is to produce the safest care, the highest quality, the highest satisfaction, the best access and the best value of any health system in the nation. The System includes approximately 7,100 primary and specialty care physicians; 10 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. The Icahn School of Medicine is one of three medical schools that have earned distinction by multiple indicators: ranked in the top 20 by U.S. News & World Report’s “Best Medical Schools”, aligned with a U.S. News & World Report’s “Honor Roll” Hospital, No. 13 in the nation for National Institutes of Health funding, and among the top 10 most innovative research institutions as ranked by the journal Nature in its Nature Innovation Index. This reflects a special level of excellence in education, clinical practice, and research. The Mount Sinai Hospital is ranked No. 18 on U.S. News & World Report’s “Honor Roll” of top U.S. hospitals; it is one of the nation’s top 20 hospitals in Cardiology/Heart Surgery, Diabetes/Endocrinology, Gastroenterology/GI Surgery, Geriatrics, Nephrology, and Neurology/Neurosurgery, and in the top 50 in four other specialties in the 2017-2018 “Best Hospitals” issue. Mount Sinai’s Kravis Children’s Hospital also is ranked in six out of ten pediatric specialties by U.S. News & World Report. The New York Eye and Ear Infirmary of Mount Sinai is ranked 12th nationally for Ophthalmology and 50th for Ear, Nose, and Throat, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s and Mount Sinai West are ranked regionally. For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.
New Haven, Conn. — Summer is here, but enjoying longer and sunnier days outdoors means your skin is vulnerable to sunburn. Experts at Yale Cancer Center (YCC) and Yale School of Medicine (YSM) say unless you take the right precautions, sun exposure (even if you don't get scorched) can damage your skin, causing wrinkles, age spots and even skin cancer. Just one sunburn during your youth doubles your chances of developing melanoma, the deadliest form of skin cancer. “Since skin cancer is the most common form of cancer in the United States—one in five people will be diagnosed with it in their lifetime—it’s important to practice sun safety before heading outdoors,” said Michael Girardi, MD, director of the Phototherapy Unit at YCC and professor of dermatology at YSM. “There is concern that rates of melanoma have been steadily rising over the last 30 years.” YCC and YSM skin cancer experts say these tips can help you avoid sun damage and reduce your chances of getting skin cancer: Generously apply high SPF sunscreen. Use a broad-spectrum, water-resistant sunscreen (SPF 30 or greater) every day. Be sure it hasn’t expired and reapply every two hours as well as after swimming or sweating. And apply everywhere on your body, not just your face and upper arms. Seal your lips from the sun’s rays. Lip balms, glosses and sticks often contain SPF ingredients. Opaque lipsticks contain pigments that help block harmful rays, according to the American Academy of Dermatology. More opaque formulas protect better. Create some shade. Clothing made of tightly woven fabric with a high ultraviolet protection factor (UPF) rating can create a physical barrier that protects your skin from the sun. Long sleeves or pants, sunglasses and a hat with a wide brim will also help shade you. Avoid peak sun hours. The sun is most damaging to skin between 10 a.m. and 2 p.m., so plan your outdoor activities before or after the sun is at its strongest. Check yourself out. Using a full-length mirror, scan your skin for spots that look suspicious (unusually shaped moles that are changing shape or are black, red or pink in color) and tell your physician. If you've previously had skin cancer, you should be checked annually by a dermatologist. At Connecticut and Rhode Island beaches this summer, volunteers from the Smilow Cancer Hospital Care Center in Waterford will be handing out sunscreen, lip balm and sun index cards at the locations and times below: Date and Hours Beach July 14th, 9:00AM - 12PM Rocky Neck State Park July 21st, 9:00AM - 12 PM McCook Beach Park Hole in the Wall Beach July 28th, 9:00AM -12PM Waterford Beach Park August 4th, 9:00AM - 12PM Ocean Beach Park August 11th, 9:00AM - 12PM Misquamicut State Beach To learn more about skin cancer screening at Smilow Cancer Hospital go to:https://www.yalecancercenter.org/patient/specialty/screening/types_cancer_screening/skin.aspx About Yale Cancer Center Yale Cancer Center (YCC) is one of only 49 National Cancer Institute (NCI-designated comprehensive cancer) centers in the nation and the only such center in southern New England. Comprehensive cancer centers play a vital role in the advancement of the NCI’s goal of reducing morbidity and mortality from cancer through scientific research, cancer prevention, and innovative cancer treatment.
Newswise — MADISON, Wis. — Modern microscopy has given scientists a front-row seat to living, breathing biology in all its Technicolor glory. But access to the best technologies can be spotty. Jan Huisken, a medical engineering investigator at the Morgridge Institute for Research at the University of Wisconsin–Madison and co-founder of light sheet microscopy, has a new project meant to bridge the technology gap. His Morgridge team has developed a portable, shareable light sheet microscope — an engineering feat that shrinks a tabletop-sized technology down to the weight and dimensions of a suitcase packed for a week’s vacation. The project can be mailed to a lab anywhere in the world, configured remotely by Morgridge engineers, and run one to three months of experiments. The microscope then either begins its mail-order journey to the next lab, or back to the Morgridge lab if a tune-up is needed — all at no cost to users. The first focus will be on sharing with the UW–Madison community. “If we succeed, this project will certainly have a huge impact in the field of fluorescence microscopy and significantly change the way we collaborate,” says Huisken. The technology targets two essential challenges. Labs lucky enough to afford a commercial microscope can keep their entire experiments in-house. But as biologists, not engineers, customizing from one project to the next is difficult and the expensive tool may drift into obsolescence, says Huisken. The budget-challenged may need to take their project to the nearest shared microscopy resource. But biology doesn’t travel well: Delicate samples may get altered or ruined along the way, and experiments may fail in the unfamiliar environment, he says. The team debuted the tool — nicknamed “Flamingo” for its one-legged stand and vertical profile — June 20 at the International Zebrafish Conference meeting at UW–Madison. It’s the perfect starting point for this device, since the zebrafish research community widely wants to use light sheet microscopy. What is light sheet? Huisken’s microscopes illuminate samples from the sides with noninvasive “sheets” of light, giving scientists the ability to image samples over hours and days from every angle. This helps generate a tremendous amount of data quickly and gives researchers a 3D view of development in an almost completely unaltered state. Zebrafish researchers use the technology because it can build striking movies of embryo, limb and organ development. But it’s also being adopted by other model organisms important to research, such as fruit flies and planaria, and for imaging early plant root growth. Susi Power, a Huisken lab member on the Flamingo development team, says the lab for years has been seeing the challenges biologists face in getting access to good imaging. One of the added benefits of the project for the Huisken lab is a kind of research crowd-sourcing. In exchange for using the technology, the lab helps expand the light-sheet user community and gets continual feedback on how to improve its core technology. “It does something magical for a biologist to have a technology like this entirely to themselves, where they can set it up and say, ‘that’s my Flamingo,’” Power says. “I think there will be a huge reward to the science.” The prototype device is built and ready to use. Ongoing work includes designing remote access to help calibrate the device from Morgridge, and building software that will give users real-time desktop and mobile access to the data. Power says the microscope is the opening project in a new Huisken lab initiative called “involv3d,” which is intended to improve collaboration and communication between different research disciplines. The Huisken lab has active members in developmental biology, medicine, physics, botany and others, and they want involv3d to bridge these fields and “help scientists profit from other scientists.” Liz Haynes, a postdoctoral fellow in the lab of UW–Madison neuroscientist Mary Halloran, says Flamingo will help address some challenges in the Halloran lab. They needed a technology that could track the neurodevelopmental consequences of gene editing changes made in zebrafish embryos, and traditional approaches were onerous. She’s looking forward to being one of Flamingo’s first customers. “I’m also excited because it is a beautiful scope and it seems really smartly designed,” Haynes says. “It’s a joy to look at. And, of course, the images you can get from (light sheet) are breathtaking.” —Brian Mattmiller, email@example.com
Newswise — PHILADELPHIA - Influenza A (flu A) hijacks host proteins for viral RNA splicing and blocking these interactions caused replication of the virus to slow, according to new research published in Nature Communications by Kristin W. Lynch, PhD, chair of the department of Biochemistry and Biophysics in the Perelman School of Medicine at the University of Pennsylvania, and doctoral student Matthew Thompson. Their results also suggest that infection with flu A may reduce splicing of some host genes, which could point to novel strategies for antiviral therapies. Influenza A virus is a common human pathogen that causes 250,000 to 500,000 deaths per year worldwide. “Although vaccines and some antiviral drugs are available, it is crucial to understand influenza virus-host interactions at a molecular level in order to identify host vulnerabilities targeted by flu viruses, which could lead to developing new therapeutic options,” said Lynch, whose lab focuses on the specific mechanisms and patterns of alternative RNA splicing and how it relates to human disease, The transcription of DNA into messenger RNA – the process of a single gene encoding a single protein – isn't as straightforward as once thought. The phenomenon of alternative RNA splicing – where a single gene can encode multiple proteins – was discovered over 30 years ago in viruses. The flu A genome is comprised of eight single-strand segments of RNA. Three of these segments use alternative splicing to produce two essential viral proteins each, which are important in helping the virus gain entry into host cells. Working with cultures of human lung cells, the team’s proposed mechanism of how flu A virus interacts with human RNA splicing machinery suggests that keeping human splicing proteins from binding to the viral genome would help to stop its replication. As a result, the researchers found that mutating sequences of the viral genome to prevent host proteins from binding caused viral RNA to splice incorrectly and eventually halt replication—thus slowing the spread of the virus in the body. A balance between the two viral messenger RNAs must be maintained for the virus to successfully infect host cells and replicate. “Regulating splicing of the two viral proteins is a fundamental step in viral-host interaction and so a potentially new anti-viral remedy,” Lynch said. For now, her team is refining their understanding of the intricacies of viral reproduction in host cells. Their hope is to one day identify a specific molecular target for antiviral medications that can be used in the clinic. This research was funded by the National Institutes of Health (R01AI125524, R35GM118048, HHSN272201400008C, U19AI10675, 4R33AI119304-03). Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $7.8 billion enterprise. The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report’s survey of research-oriented medical schools. The School is consistently among the nation’s top recipients of funding from the National Institutes of Health, with $405 million awarded in the 2017 fiscal year. The University of Pennsylvania Health System’s patient care facilities include: The Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center — which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report — Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; Penn Wissahickon Hospice; and Pennsylvania Hospital – the nation’s first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine, and Princeton House Behavioral Health, a leading provider of highly skilled and compassionate behavioral healthcare. Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2017, Penn Medicine provided $500 million to benefit our community.
Newswise — DALLAS – June 22, 2018 – Men often tolerate stress urinary incontinence for more than two years before seeking medical help – and one-third put up with it for more than five years, making it important for doctors to check for this problem, a new study from UT Southwestern researchers advises. The study, published in the journal Urology, calls on men’s general practitioners and urologists to perform a standing cough test, in which a patient coughs while the doctor watches for any accidental urine release, as a routine part of their male patients’ physicals. “Our goal is to spread the word that effective and safe treatments exist for men with stress urinary incontinence, but also to facilitate an immediate and accurate diagnosis among stress urinary incontinence patients,” said Dr. Joceline Fuchs, Assistant Instructor of Urology and first author of the study. Stress urinary incontinence (SUI) occurs when physical activity or exertion – a cough, heavy lifting, exercise – causes the bladder to leak urine. About 13 million Americans suffer from some degree of incontinence, with women accounting for 85 percent of cases. However, some men who have had prostate cancer treatments involving surgery (prostatectomies) develop the condition. More about incontinence Q&A by Dr. Gary LeMack UTSW Incontinence Services Urinary Incontinence for Women Urology journal article Even though men are slow to complain, “Male SUI is rare but is known to have significant negative psychosocial and emotional effects and represents a common reason for post-treatment anxiety and depression,” said Dr. Allen Morey, Professor of Urology at UT Southwestern and senior author of the study. But there are simple and safe solutions – including minor surgeries that can either help boost a weakened sphincter muscle for patients with minimal leakage (the sling procedure), or replace the sphincter muscle altogether (installation of an artificial urinary sphincter) for more severe cases of leakage. “Using new diagnostic techniques, we are now able to accurately diagnose and streamline treatment recommendations to resolve this bothersome problem for our patients,” said Dr. Morey, who holds the Distinguished Chair in Urology for Urologic Reconstruction, in Honor of Allen F. Morey, M.D., and the Paul C. Peters, M.D. Chair in Urology. “This study highlights an opportunity for improvement.” During the study, UT Southwestern researchers reviewed the cases of 572 men evaluated for anti-incontinence surgery in Dallas between 2007 and 2017. They found the median length of time the men had waited to seek treatment for their SUI was 32 months, with almost a third having waited more than five years. Patients in their 80s had waited a median of more than seven years. Most recovery of urinary control occurs within the first 12 months after a prostatectomy, the study notes. Beyond the first year, improvement is unlikely. Care for such patients should include urologist-directed treatment plans that focus on non-cancer problems such as incontinence, researchers said. Some treatment delay may also be tied to patient reluctance to undergo more surgery or due to limited geographic access to appropriate specialists, researchers said. However, patient satisfaction and quality of life improvement measures for those who do undergo anti-incontinence surgery are high, ranging from 73 to 90 percent, according to the study. The American Cancer Society Prostate Cancer Survivorship Care Guidelines recommend screening for long-term functional effects such as urinary incontinence after prostate cancer treatment, the study points out, and those guidelines have been endorsed by the American Society of Clinical Oncology. Incontinence help UT Southwestern physicians offer patients who suffer from incontinence outstanding expertise in urodynamic studies – the use of X-ray imaging to help diagnose the causes of incontinence. UTSW physicians were the first in North Texas to offer the botulinum toxin injection for neurogenic bladder dysfunction in men and women. UTSW physicians offer unique treatments, like electrical stimulation, to patients who are unresponsive to other therapies and others that are offered at only a few medical institutions in the world. Treatments can include: Behavioral therapy Biofeedback Drug therapy Exercise In-office procedures Incontinence surgery Palliative measures About UT Southwestern Medical Center UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education. The institution’s faculty has received six Nobel Prizes, and includes 22 members of the National Academy of Sciences, 16 members of the National Academy of Medicine, and 15 Howard Hughes Medical Institute Investigators. The faculty of more than 2,700 is responsible for groundbreaking medical advances and is committed to translating science-driven research quickly to new clinical treatments. UT Southwestern physicians provide care in about 80 specialties to more than 100,000 hospitalized patients, 600,000 emergency room cases, and oversee approximately 2.2 million outpatient visits a year.
Newswise — MADISON, Wis. — The human gut is teeming with microbes, each interacting with one another in a mind-boggling network of positive and negative exchanges. Some produce substances that serve as food for other microbes, while others produce toxins — antibiotics — that kill their neighbors. Scientists have been challenged trying to understand how this collection of gut microbes known as the microbiome is formed, how it changes over time and how it is affected by disturbances like antibiotics used to treat illnesses. A new study from Ophelia Venturelli, a biochemistry professor at the University of Wisconsin–Madison, and her collaborators at the University of California, Berkeley, may help alleviate some of that difficulty. Published June 21 in the journal Molecular Systems Biology, the study provides a platform for predicting how microbial gut communities work and represents a first step toward understanding how to manipulate the properties of the gut ecosystem. This could allow scientists to, for example, design a probiotic that persists in the gut or tailor a diet to positively influence human health. “We know very little about the ecological interactions of the gut microbiome,” Venturelli says. “Many studies have focused on cataloging all of the microbes present, which is very useful, but we wanted to try to understand the rules governing their assembly into communities, how stability is achieved, and how they respond to perturbations as well.” By learning these rules, researchers say they can better predict interactions between microbes using computational tools instead of performing laborious and time-consuming laboratory experiments. The data can also start to answer questions about how pathogens cause damage when they invade communities, and how to prevent it. For the study, the researchers chose 12 bacterial types present in the human gut. They represented the diversity of the gut microbiome and the majority have been shown to significantly affect human health. They have associations with diseases such as diabetes, irritable bowel syndrome, Crohn’s disease and colon cancer. The team collected data on what are called pairwise interactions, which means each bacterial species was paired with just one other to study how the two interacted, without worrying about what all of the others were doing. This was done for every single possible pairing in the 12-member community. The researchers fed data about the pairwise interactions, along with data on each individual species, into a dynamic model to decipher how all of the bacteria would likely interact when combined. They found the pairwise data alone was sufficient to predict how the larger community assembles. “This model allows us to better understand and make predictions about the gut microbiome with fewer measurements,” Venturelli explains. “We don’t need to measure every single possible community of, say, three, four or five of a set of species. We just need to measure all the pairs, which still represents a very large number, to be able to predict the dynamics of the whole gut.” While this is still a challenge, Venturelli says it will significantly reduce the number of measurements scientists need to make. The researchers also looked at which species seemed to be the most important in the community by measuring substances microbes produce, called metabolites. To their surprise, “the metabolite data was not able to predict the role of important species in the community,” Venturelli says. She and the research team then tested the model’s predictive power by trying to estimate the characteristics of different combinations of their 12 chosen bacteria. Although not perfect, the model did well at predicting dynamic behaviors. Additionally, the team found more positive interactions between microbes in the community than they expected based on other studies that have shown mostly negative interactions. “We found there’s a balance between positive and negative interactions and the negative interactions kind of provide a stabilizing force for the community,” Venturelli says. “We are beginning to understand the design principles of stability of the gut microbes and what allows a community to recover from perturbations.” The model allows the scientist to now begin to ask questions about the composition and dynamics of thousands of microbial communities. “Without a model, we are basically just blindly testing things without really knowing what we are doing and what the consequences are when we are, for example, trying to design an intervention,” she says. “Having a model is a first step toward being able to manipulate the gut ecosystem in a way that can benefit human health.” This work was supported by the Defense Advanced Research Projects Agency (DARPA) (HR0011516183). —Kaine Korzekwa, firstname.lastname@example.org, (608) 265-4002
Newswise — The fifth annual Metastatic Breast Cancer Conference invites participants from around the world to discuss ongoing research, showcase new ideas from young scientists, and bring together advocates who are working with metastatic breast cancer patients. This year, the conference will be hosted by the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins School of Medicine in Baltimore on Nov. 15 and 16. The Metastatic Breast Cancer Conference was established in 2014 by Theresa’s Research Foundation, with leadership from Matthew Ellis, Ph.D., M.B., McNair Scholar at Baylor College of Medicine, and Danny Welch, Ph.D., at the University of Kansas Medical Center. The first conference was held at the University of Kansas Medical Center in Kansas City, Kansas, in 2014. For the past three years, it was hosted by Baylor College of Medicine in Houston. The conference is unique from other breast cancer-centered conferences due to its specific focus on addressing metastatic disease as a major, but yet unmet, clinical need. For 2018, it moves to Baltimore under the guidance of Vered Stearns, M.D., and Andrew Ewald, Ph.D., at the Johns Hopkins Kimmel Cancer Center. Registration for the conference can be done at the Johns Hopkins Medicine website. Stearns said the goal of this year’s conference is to bring together a diverse audience in a collaborative environment to seek curative approaches for metastatic breast cancer patients. “There has been frustration on the patient side and from advocates with the lack of emphasis with metastatic/stage IV breast cancer,” Stearns said. “Less than 7 percent of funding goes toward metastatic breast cancer research. We want to bring in the best researchers, the best ideas, and invite patients and patient advocates to Johns Hopkins to find new ways and get them into the thought process.” The conference will feature discussions about therapy, predictive models, drug development and more. The keynote addresses, one each day, will focus on how reprogramming the tumor microenvironment determines metastatic progress of breast cancer and management of metastatic inherited breast cancer. Invited speakers from the United States and Europe will bring their knowledge and expertise to the conference and seek to inspire conversation and collaboration on new approaches regarding metastatic breast cancer. “Metastatic breast cancer needs a dedicated, long-term effort to find curative approaches. This conference helps to benchmark these efforts and create the collaborative research environment that is a prerequisite for progress,” Ellis said. Abstract submissions are encouraged, and the top five will be chosen for oral presentation during a Friday morning session. The others will be on display as posters. The submission period will open July 5 and close Sept. 5. The conference will be held at the Thomas B. Turner Auditorium on the Johns Hopkins medical campus in Baltimore. It is co-provided by the Baylor College of Medicine and Theresa’s Research Foundation. For more information, visit the Metastatic Breast Cancer Conference website.
Newswise — Promising experimental cancer chemotherapy drugs may help knock out another life-threatening disease: tuberculosis (TB). A new study published by scientists at Texas Biomedical Research Institute in San Antonio pinpoints a mechanism in regulating cell death called apoptosis that is a potential new target for helping to control the bacterial infection (Mycobacterium tuberculosis or M.tb) that causes the lung disease TB. Lead author of the newly-published study, Eusondia Arnett, Ph.D., a Staff Scientist at Texas Biomed, and her colleagues have been testing this theory for about two years. Using human immune cells called macrophages and infecting them with M.tb in the lab, scientists were able to test their theory that pathways regulated by a master regulator of gene expression – a host protein called PPARᵧ -- are a good target for intervention to halt the progression of the disease. When Dr. Arnett’s team treated M.tb-infected macrophages with Mcl-1 inhibitors that target this important apoptotic pathway, they found a reduction of M.tb growth by 80%. Almost 20 people develop TB and four people die from the disease every minute, somewhere in the world. TB is now the world’s deadliest single infectious disease, surpassing AIDS. “If we can stimulate apoptosis in M.tb-infected cells, then we can reduce M.tb growth, Dr. Arnett explained. “Induction of apoptosis and subsequent reduced M.tb growth should ultimately result in less inflammation and damage to the lungs, and increased control of TB.” Tuberculosis infection also creates granulomas in the lungs – dense cellular structures that are the body’s attempt to wall off an infection it is unable to eliminate. However, granulomas also provide a niche for the bacterium to become recalcitrant to antibiotics, Dr. Arnett’s study showed that these experimental cancer drugs also reduced M.tb growth in granulomas using a human granuloma model holding promise for the activity of these drugs in human and animal models. Cancer drugs similar to those used in the study are already in Phase II of Food and Drug Administration clinical trials. The next step for testing on the TB front will be to find out the effectiveness of this therapy in a mouse model, and then finally, in a nonhuman primate before moving on to human trials. “It’s very exciting that these have already gone through a lot of testing in humans and we can capitalize on that,” Dr. Arnett said, explaining this could speed up the time it takes to get a new treatment to patients with tuberculosis. This study is a great example of why basic scientific research is so important,” said senior investigator of the study Dr. Larry Schlesinger, the President & CEO of Texas Biomed. “When we study important host cell pathways for disease, we can find relationships we didn’t even know existed. We can forge new ways to use current knowledge to create novel strategies for host-directed therapy for infection to be used along with antibiotics.” The study is published in the June 21, 2018 edition of the Journal PLOS Pathogens. This work was supported in part by a National Institutes of Health T32 Fellowship, “Molecular Mechanisms of Lung Inflammation”, award # T32HL007946 (to EA) and a National Institutes of Health T32 Fellowship, "Interdisciplinary Program in Microbe-Host Biology, award #1-T32-AI-112542 (to EA), and National Institutes of Health grants AI059639 and AI052458 (to LSS). ### Texas Biomed is one of the world's leading independent biomedical research institutions dedicated to advancing health worldwide through innovative biomedical research. The Institute is home to the Southwest National Primate Research Center (SNPRC) and provides broad services in primate research. SNPRC contributes to a national network of National Primate Research Centers (NPRCs) with specialized technologies, capabilities and primate resources, many of which are unique to the SNPRC. The Center also serves investigators around the globe with research and technical procedures for collaborative projects. For more information on Texas Biomed, go to www.TxBiomed.org or for more information on SNPRC, visit www.SNPRC.org.